

Appendix: Tables

1.	Sales January to December 2019 and 2018.....	2
2.	Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018.....	3
3.	Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018.....	4
4.	Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018	5
5.	Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018.....	6
6.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth	7
7.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States.....	8
8.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe.....	9
9.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan	10
10.	Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*	11
11.	Roche Group consolidated income statement for the twelve months ended 31 December 2019.....	12
12.	Roche Group core results reconciliation – Full Year 2019	13
13.	Divisional core results reconciliation – Full Year 2019	14
14.	Roche Group consolidated balance sheet	15
15.	Roche Group consolidated statement of cash flows	16

1. Sales January to December 2019 and 2018

CHF millions	Twelve months ended 31 December		% change	
	2019	2018	At CER	In CHF
Pharmaceuticals Division	48,516	43,967	11	10
United States	26,711	23,233	13	15
Europe	8,453	8,693	1	-3
Japan	4,143	3,701	9	12
International*	9,209	8,340	15	10
Diagnostics Division	12,950	12,879	3	1
Roche Group	61,466	56,846	9	8

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

2. Quarterly sales and constant exchange rate sales growth by Division in 2019 and 2018

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Pharmaceuticals Division	11,265	8	11,927	10	12,267	11	12,365	15	11,957	8
United States	6,041	14	6,623	14	6,747	13	6,666	14	6,675	11
Europe	2,086	-6	2,101	-6	2,120	-2	2,089	5	2,143	6
Japan	1,001	-5	941	7	1,047	12	1,088	14	1,067	3
International*	2,137	14	2,262	17	2,353	16	2,522	27	2,072	2
Diagnostics Division	3,501	10	2,899	1	3,376	4	3,232	6	3,443	1
Roche Group	14,766	9	14,826	8	15,643	9	15,597	13	15,400	6

*Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

3. Pharmaceuticals Division – Top-selling pharmaceuticals sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018

Top-selling pharmaceuticals January – December 2019	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	7,073	4	3,019	2	1,794	2	871	0	1,389	13
MabThera/Rituxan	6,477	-4	4,488	3	590	-33	109	-44	1,290	-1
Herceptin	6,039	-12	2,707	-8	1,013	-43	243	-5	2,076	10
Ocrevus	3,708	57	3,049	44	495	148	-	-	164	161
Perjeta	3,522	29	1,528	13	1,092	24	280	90	622	71
Actemra/RoActemra	2,311	8	944	8	705	4	398	9	264	14
Xolair	1,969	1	1,969	1	-	-	-	-	-	-
Tecentriq	1,875	143	1,180	148	349	138	188	126	158	138
Lucentis	1,826	8	1,826	8	-	-	-	-	-	-
Kadcyla	1,393	45	635	74	432	19	82	7	244	56

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

4. Pharmaceuticals Division – New products sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018

New products	Total		United States		Europe		Japan		International*	
January - December 2019	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Erivedge	279	10	185	14	62	-10	-	-	32	38
Perjeta	3,522	29	1,528	13	1,092	24	280	90	622	71
Kadcyla	1,393	45	635	74	432	19	82	7	244	56
Gazyva/Gazyvaro	552	43	249	25	174	32	66	397	63	47
Esbriet	1,129	9	806	5	263	18	-	-	60	34
Cotellic	57	-2	11	-25	31	-9	-	-	15	50
Alecensa	876	38	329	14	212	123	217	12	118	86
Tecentriq	1,875	143	1,180	148	349	138	188	126	158	138
Ocrevus	3,708	57	3,049	44	495	148	-	-	164	161
Hemlibra	1,380	**	943	**	165	308	232	**	40	**
Xofluza	10	-29	8	-42	-	-	-	-	2	-
Polivy	51	-	51	-	-	-	-	-	-	-
Rozlytrek	7	-	7	-	-	-	-	-	-	-

5. Top 20 Pharmaceuticals Division product sales and constant exchange rate growth YTD December 2019 vs. YTD December 2018

CHF millions	Total		United States		Europe		Japan		International*	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%	CHF m	%
Avastin	7,073	4	3,019	2	1,794	2	871	0	1,389	13
MabThera/Rituxan	6,477	-4	4,488	3	590	-33	109	-44	1,290	-1
Herceptin	6,039	-12	2,707	-8	1,013	-43	243	-5	2,076	10
Ocrevus	3,708	57	3,049	44	495	148	-	-	164	161
Perjeta	3,522	29	1,528	13	1,092	24	280	90	622	71
Actemra/RoActemra	2,311	8	944	8	705	4	398	9	264	14
Xolair	1,969	1	1,969	1	-	-	-	-	-	-
Tecentriq	1,875	143	1,180	148	349	138	188	126	158	138
Lucentis	1,826	8	1,826	8	-	-	-	-	-	-
Kadcyla	1,393	45	635	74	432	19	82	7	244	56
Hemlibra	1,380	**	943	**	165	308	232	**	40	**
Activase/TNKase	1,332	2	1,278	2	-	-	-	-	54	2
Esbriet	1,129	9	806	5	263	18	-	-	60	34
Alecensa	876	38	329	14	212	123	217	12	118	86
Pulmozyme	751	2	527	2	132	3	1	23	91	-1
CellCept	656	0	83	-23	173	0	85	3	315	7
Mircera	591	10	-	-	67	-9	202	-4	322	28
Gazyva	552	43	249	25	174	32	66	397	63	47
Xeloda	406	-4	22	-38	17	2	73	-36	294	14
Tamiflu	377	0	43	-75	81	234	97	-1	156	75

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

6. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Avastin	1,741	5	1,798	9	1,861	6	1,806	8	1,608	-6
MabThera/Rituxan	1,642	-6	1,694	-3	1,645	-5	1,620	-1	1,518	-6
Herceptin	1,675	-3	1,666	-6	1,598	-12	1,535	-7	1,240	-24
Ocrevus	680	83	836	67	899	59	929	48	1,044	55
Perjeta	761	35	868	41	887	29	910	33	857	16
Actemra/RoActemra	582	14	534	6	601	10	571	9	605	5
Xolair	486	12	469	1	503	2	513	3	484	0
Tecentriq	248	89	336	135	446	146	515	154	578	136
Lucentis	428	47	457	11	471	9	442	7	456	7
Kadcyla	251	7	291	24	345	42	369	54	388	57
Hemlibra	111	*	219	*	316	*	386	*	459	313
Activase/TNKase	315	4	362	7	324	-3	334	5	312	0
Esbriet	292	26	250	10	282	13	281	6	316	9
Alecensa	200	69	196	61	225	41	235	50	220	11
Pulmozyme	202	3	182	6	189	0	191	7	189	-5
CellCept	161	-9	163	4	162	-4	177	3	154	-3
Mircera	134	-4	142	16	140	10	167	11	142	5
Gazyva	109	44	115	35	126	38	149	45	162	51
Xeloda	101	-8	108	5	108	-2	103	-4	87	-13
Tamiflu	45	-67	179	-40	48	110	59	369	91	104

* Over 500%

7. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth United States

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Avastin	732	3	824	12	806	7	742	1	647	-11
MabThera/Rituxan	1,097	7	1,168	9	1,113	-1	1,108	4	1,099	1
Herceptin	703	0	791	3	718	-8	665	-6	533	-24
Ocrevus	581	59	715	54	741	46	760	35	833	44
Perjeta	357	38	412	36	376	9	370	8	370	4
Actemra/RoActemra	234	17	212	5	248	11	236	11	248	6
Xolair	486	12	469	1	503	2	513	3	484	0
Tecentriq	140	21	216	91	292	158	329	198	343	146
Lucentis	428	47	457	11	471	9	442	7	456	7
Kadcyla	90	1	125	39	153	62	170	87	187	108
Hemlibra	76	*	166	*	215	*	254	*	308	302
Activase/TNKase	302	4	351	7	310	-4	320	5	297	-1
Esbriet	219	33	174	7	200	9	199	0	233	6
Alecensa	80	44	67	14	82	5	82	15	98	23
Pulmozyme	142	4	119	6	134	-1	138	9	136	-4
CellCept	21	-24	21	-20	22	-25	23	-30	17	-15
Mircera	-	-	-	-	-	-	-	-	-	-
Gazyva	50	25	55	22	55	8	65	24	74	48
Xeloda	9	183	9	10	6	-41	3	-63	4	-53
Tamiflu	1	-100	24	-86	7	*	-	-	12	*

* Over 500%

8. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Europe

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Avastin	450	1	461	1	459	3	435	4	439	1
MabThera/Rituxan	185	-46	171	-38	152	-35	147	-26	120	-33
Herceptin	354	-34	300	-44	268	-47	233	-42	212	-39
Ocrevus	76	*	92	232	119	149	127	154	157	112
Perjeta	244	25	267	27	274	28	264	18	287	21
Actemra/RoActemra	178	8	174	4	181	8	172	3	178	3
Xolair	-	-	-	-	-	-	-	-	-	-
Tecentriq	46	286	57	158	77	112	93	113	122	172
Lucentis	-	-	-	-	-	-	-	-	-	-
Kadcyla	96	9	97	9	107	18	108	20	120	28
Hemlibra	20	*	26	450	37	*	45	211	57	202
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	61	14	62	14	66	18	66	26	69	16
Alecensa	39	217	46	182	50	154	57	164	59	58
Pulmozyme	34	8	35	8	33	3	31	2	33	-2
CellCept	45	0	44	2	43	-2	43	3	43	-1
Mircera	18	-8	17	-11	17	-7	17	-8	16	-8
Gazyva	37	52	38	31	42	31	44	30	50	38
Xeloda	4	-27	4	-13	4	0	5	16	4	7
Tamiflu	3	-77	28	38	13	*	34	*	6	145

* Over 500%

9. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth Japan

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Avastin	230	2	194	2	230	4	241	9	206	-13
MabThera/Rituxan	37	-54	28	-50	30	-42	26	-45	25	-37
Herceptin	66	-17	56	-9	67	6	62	-1	58	-15
Ocrevus	-	-	-	-	-	-	-	-	-	-
Perjeta	46	35	51	74	69	99	81	125	79	67
Actemra/RoActemra	99	13	86	13	102	11	107	13	103	1
Xolair	-	-	-	-	-	-	-	-	-	-
Tecentriq	37	-	33	-	42	169	50	66	63	68
Lucentis	-	-	-	-	-	-	-	-	-	-
Kadcyla	20	3	18	12	22	11	22	10	20	-5
Hemlibra	13	-	25	-	57	*	71	*	79	472
Activase/TNKase	-	-	-	-	-	-	-	-	-	-
Esbriet	-	-	-	-	-	-	-	-	-	-
Alecensa	53	20	47	24	58	16	57	14	55	-1
Pulmozyme	1	26	-	-	-	-	-	-	1	14
CellCept	22	-4	19	8	23	7	21	1	22	-1
Mircera	58	-4	45	3	55	4	51	-6	51	-14
Gazyva	8	-	8	-	13	-	25	390	20	145
Xeloda	30	1	22	-14	21	-30	16	-44	14	-53
Tamiflu	16	-73	71	-6	1	153	-	-	25	50

* Over 500%

10. Top 20 Pharmaceuticals Division quarterly product sales and quarterly constant exchange rate sales growth International*

CHF millions	Q4 2018	% change vs. Q4 2017	Q1 2019	% change vs. Q1 2018	Q2 2019	% change vs. Q2 2018	Q3 2019	% change vs. Q3 2018	Q4 2019	% change vs. Q4 2018
Avastin	329	15	319	16	366	10	388	29	316	0
MabThera/Rituxan	323	12	327	-4	350	8	339	3	274	-11
Herceptin	552	32	519	26	545	17	575	20	437	-16
Ocrevus	23	459	29	261	39	173	42	118	54	155
Perjeta	114	46	138	83	168	73	195	122	121	19
Actemra/RoActemra	71	24	62	10	70	15	56	16	76	15
Xolair	-	-	-	-	-	-	-	-	-	-
Tecentriq	25	458	30	262	35	127	43	132	50	109
Lucentis	-	-	-	-	-	-	-	-	-	-
Kadcyla	45	14	51	32	63	62	69	78	61	50
Hemlibra	2	-	2	-	7	-	16	**	15	**
Activase/TNKase	13	3	11	-10	14	6	14	2	15	8
Esbriet	12	-5	14	37	16	49	16	20	14	31
Alecensa	28	343	36	278	35	177	39	154	8	-64
Pulmozyme	25	-8	28	4	22	0	22	5	19	-15
CellCept	73	-11	79	13	74	-1	90	17	72	-1
Mircera	58	-3	80	35	68	21	99	27	75	28
Gazyva	14	24	14	31	16	101	15	31	18	43
Xeloda	58	-17	73	13	77	15	79	17	65	10
Tamiflu	25	11	56	55	27	30	25	270	48	86

* Asia-Pacific, EEMEA (Eastern Europe, Middle East and Africa), Latin America, Canada, others

** Over 500%

11. Roche Group consolidated income statement for the twelve months ended 31 December 2019

in millions of CHF

	Pharma- ceuticals	Diagnostics	Corporate	Group
Sales	48,516	12,950	-	61,466
Royalties and other operating income	2,198	87	-	2,285
Cost of sales	(11,593)	(6,758)	-	(18,351)
Marketing and distribution	(7,905)	(3,055)	-	(10,960)
Research and development	(11,221)	(1,553)	-	(12,774)
General and administration	(2,049)	(1,429)	(640)	(4,118)
Operating profit	17,946	242	(640)	17,548
Financing costs				(993)
Other financial income (expense)				59
Profit before taxes				16,614
Income taxes				(2,506)
Net income				14,108
Attributable to				
- Roche shareholders				13,497
- Non-controlling interests				611
Earnings per share and non-voting equity security				
Basic (CHF)				15.77
Diluted (CHF)				15.62

12. Roche Group core results reconciliation – Full Year 2019

in millions of CHF

	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Global issues	Normalisation of ECP tax benefit	Core
Sales	61,466	-	-	-	-	-	-	-	-	61,466
Royalties and other operating income	2,285	-	-	-	-	-	-	-	-	2,285
Cost of sales	(18,351)	380	1,264	344	-	-	-	-	-	(16,363)
Marketing and distribution	(10,960)	405	41	1	-	-	-	-	-	(10,513)
Research and development	(12,774)	219	227	632	-	-	-	-	-	(11,696)
General and administration	(4,118)	202	-	779	(43)	481	(1)	-	-	(2,700)
Operating profit	17,548	1,206	1,532	1,756	(43)	481	(1)	-	-	22,479
Financing costs	(993)	-	-	-	14	17	-	-	-	(962)
Other financial income (expense)	59	-	-	-	-	-	-	-	-	59
Profit before taxes	16,614	1,206	1,532	1,756	(29)	498	(1)	-	-	21,576
Income taxes	(2,506)	(236)	(152)	(186)	(23)	(81)	-	(236)	(94)	(3,514)
Net income	14,108	970	1,380	1,570	(52)	417	(1)	(236)	(94)	18,062
Attributable to										
- Roche shareholders	13,497	946	1,375	1,570	(52)	411	(1)	(236)	(94)	17,416
- Non-controlling interests	611	24	5	-	-	6	-	-	-	646
EPS - diluted (CHF)	15.62	1.09	1.59	1.82	(0.06)	0.48	-	(0.27)	(0.11)	20.16

13. Divisional core results reconciliation – Full Year 2019

in millions of CHF								
	IFRS	Global restructuring	Intangibles amortisation	Intangibles impairment	Mergers and acquisitions and alliance transactions	Legal & environmental	Pension plan settlements	Core
Pharmaceuticals								
Sales	48,516	-	-	-	-	-	-	48,516
Royalties and other operating income	2,198	-	-	-	-	-	-	2,198
Cost of sales	(11,593)	260	1,153	-	-	-	-	(10,180)
Marketing and distribution	(7,905)	267	33	1	-	-	-	(7,604)
Research and development	(11,221)	141	220	632	-	-	-	(10,228)
General and administration	(2,049)	68	-	-	80	215	(1)	(1,687)
Operating profit	17,946	736	1,406	633	80	215	(1)	21,015
Diagnostics								
Sales	12,950	-	-	-	-	-	-	12,950
Royalties and other operating income	87	-	-	-	-	-	-	87
Cost of sales	(6,758)	120	111	344	-	-	-	(6,183)
Marketing and distribution	(3,055)	138	8	-	-	-	-	(2,909)
Research and development	(1,553)	78	7	-	-	-	-	(1,468)
General and administration	(1,429)	5	-	779	(123)	257	-	(511)
Operating profit	242	341	126	1,123	(123)	257	-	1,966
Corporate								
General and administration	(640)	129	-	-	-	9	-	(502)
Operating profit	(640)	129	-	-	-	9	-	(502)

14. Roche Group consolidated balance sheet

in millions of CHF	31 December 2019	31 December 2018	31 December 2017
Non-current assets			
Property, plant and equipment	22,173	21,818	20,912
Right-of-use assets	1,145	0	0
Goodwill	12,456	8,948	10,077
Intangible assets	8,358	9,346	8,368
Deferred tax assets	5,211	3,895	3,576
Defined benefit plan assets	945	877	801
Other non-current assets	1,549	1,389	1,370
Total non-current assets	51,837	46,273	45,104
Current assets			
Inventories	6,055	6,621	7,407
Accounts receivable	10,440	9,776	9,577
Current income tax assets	237	208	348
Other current assets	2,664	2,521	2,243
Marketable securities	5,783	6,437	7,278
Cash and cash equivalents	6,075	6,681	4,719
Total current assets	31,254	32,244	31,572
Total assets	83,091	78,517	76,676
Non-current liabilities			
Long-term debt	(12,668)	(16,077)	(15,839)
Net deferred tax liabilities	(298)	(384)	(495)
Defined benefit plan liabilities	(7,480)	(7,017)	(7,421)
Provisions	(1,515)	(1,452)	(1,548)
Other non-current liabilities	(1,144)	(188)	(206)
Total non-current liabilities	(23,105)	(25,118)	(25,509)
Current liabilities			
Short-term debt	(1,695)	(2,693)	(3,121)
Current income tax liabilities	(3,838)	(3,808)	(3,408)
Provisions	(2,885)	(2,329)	(2,042)
Accounts payable	(3,822)	(3,526)	(3,454)
Other current liabilities	(11,879)	(10,677)	(10,135)
Total current liabilities	(24,119)	(23,033)	(22,160)
Total liabilities	(47,224)	(48,151)	(47,669)
Total net assets	35,867	30,366	29,007
Equity			
Capital and reserves attributable to Roche shareholders	32,747	27,622	26,441
Equity attributable to non-controlling interests	3,120	2,744	2,566
Total equity	35,867	30,366	29,007

15. Roche Group consolidated statement of cash flows

in millions of CHF

	FY 2019	FY 2018
Cash flows from operating activities		
Cash generated from operations	26,793	24,424
(Increase) decrease in net working capital	149	176
Payments made for defined benefit plans	(676)	(785)
Utilisation of provisions	(828)	(883)
Disposal of products	490	335
Other operating cash flows	-	-
Cash flows from operating activities, before income taxes paid	25,928	23,267
Income taxes paid	(3,543)	(3,288)
Total cash flows from operating activities	22,385	19,979
Cash flows from investing activities		
Purchase of property, plant and equipment	(3,503)	(4,043)
Purchase of intangible assets	(1,393)	(879)
Disposal of property, plant and equipment	71	146
Disposal of intangible assets	2	-
Business combinations	(4,706)	(3,374)
Divestment of subsidiaries	3	1
Interest and dividends received	69	24
Sales of marketable securities	587	566
Purchases of marketable securities	(221)	(412)
Sales (purchases) of money market instruments and time accounts over three months, net	461	672
Other investing cash flows	(4)	104
Total cash flows from investing activities	(8,634)	(7,195)
Cash flows from financing activities		
Proceeds from issue of bonds and notes	-	2,252
Redemption and repurchase of bonds and notes	(5,414)	(2,152)
Increase (decrease) in commercial paper	858	(199)
Increase (decrease) in other debt	153	(23)
Hedging and collateral arrangements	(137)	12
Changes in ownership interests in subsidiaries	(21)	(2,287)
Changes in non-controlling interests	-	-
Equity contribution by non-controlling interests - capital injection	13	-
Interest paid	(624)	(593)
Principal portion of lease liabilities paid	(372)	-
Dividends paid	(7,682)	(7,253)
Equity-settled equity compensation plans, net of transactions in own equity	(947)	(448)
Other financing cash flows	-	-
Total cash flows from financing activities	(14,173)	(10,691)
Net effect of currency translation on cash and cash equivalents	(184)	(131)
Increase (decrease) in cash and cash equivalents	(606)	1,962
Cash and cash equivalents at beginning of period	6,681	4,719
Cash and cash equivalents at end of period	6,075	6,681